Reprab Study: PLD + Trabectedin Rechallenge
RECHALLENGE WITH PEGYLATED LIPOSOMAL DOXORUBICIN ADDED TO TRABECTEDIN IN RECURRENT OVARIAN CANCER: A MULTICENTER, PROSPECTIVE TRIAL
Relapsed Ovarian Cancer
DRUG: PLD and Trabectedin rechallenge
Objective Response Rate, 30 months
To demonstrate that rechallenge with pegylated liposomal doxorubicin (PLD) with the combination of trabectedin (YondelisÂ®) is active (objective response rate) in relapsed ovarian cancer patients who have already received pegylated liposomal doxorubicin and progress within 6-12 months after the end of last platinum or in fully platinum sensitive patients not able to receive or not willing to receive other platinum treatments